Dr. Michael C. Soulen, MD

Dr. Soulen practices at Good Shepherd Penn Partners - HOPD (3400 Spruce Street, White Bldg 1st Flr) in Philadelphia, Pennsylvania.

Dr. Soulen's NPI, 1447296579, was assigned on June 20, 2006. Dr. Soulen graduated from Perelman School of Medicine - Philadelphia in 1984. Dr. Soulen holds Pennsylvania license MD044138E.

Dr. Soulen's primary practice is Good Shepherd Penn Partners - HOPD (3400 Spruce Street, White Bldg 1st Flr), at 3400 Spruce Street, White Bldg 1st Flr, Philadelphia, PA 19104.

Dr. Soulen's primary practice is Good Shepherd Penn Partners - HOPD (3400 Spruce Street, White Bldg 1st Flr) in Philadelphia, Pennsylvania. Dr. Soulen is also affiliated with Hospital of the University of Pennsylvania. The medical group on file is Penn Medicine Lancaster General Health. Dmand AI also links Dr. Soulen to 2 more hospitals, each named with a free account. Dr. Soulen's employer is on file too: a hospital.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Soulen practices, 4 sites in all. Vendor and product names are available with a free account.

Vascular and interventional radiology is Dr. Soulen's primary specialty in the NPI Registry, under taxonomy code 2085R0204X. Dr. Soulen is board certified in interventional radiology and diagnostic radiology by the American Board of Radiology. Dmand AI has Dr. Soulen's licenses on file in 4 states: Pennsylvania, New Jersey, North Carolina and Maryland.

CMS data shows 323 Medicare services from Dr. Soulen across 9 procedure codes in 2024, for 151 Medicare patients. Medicare paid $35,444 for them.

CMS counts 151 Medicare patients who saw Dr. Soulen in 2024. The largest group is 65 to 74, with 75 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 15% are also on Medicaid. Their average risk score is 3.50, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Soulen's median patient age at 66, with 46% women.

In 2017, Dr. Soulen wrote 12 Medicare Part D claims. Every claim was for a generic drug. They cover 1 drug, with $90 in total drug cost. In 2016, CMS named 36 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 85 out of 100 for Dr. Soulen for performance year 2024, reported as part of a group. Dr. Soulen accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Soulen as offering telehealth.

Dmand AI links 211 papers to Dr. Soulen, published from 2005 to 2025. 2020 was the busiest year, with 12. The most frequent topics are Liver Neoplasms, Carcinoma, Hepatocellular and Chemoembolization, Therapeutic. Dr. Soulen has published most often in J Vasc Interv Radiol. Dr. Soulen's most frequent co-authors are Jeffrey I. Mondschein, MD, S. William Stavropoulos, MD and Mandeep Sanat Dagli, MD.

Dmand AI links Dr. Soulen to 12 clinical trials, 3 of them phase 1 studies. 5 are still active or recruiting. Conditions studied include Carcinoma, Hepatocellular, Neuroendocrine Tumors and Liver Neoplasms. Abramson Cancer Center at Penn Medicine sponsors the most, 8. Open Payments lists research payments to Dr. Soulen that name 1 trial.

CMS Open Payments shows 138 general payments to Dr. Soulen from 17 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 73% of the total. Guerbet LLC paid the most, $232,162. It also lists 1 research payment totaling $149 in 2016, naming 1 clinical trial.

Dmand AI lists 6 awards for Dr. Soulen, most recently America's Top Doctors in 2014.

Dr. Soulen graduated from Perelman School of Medicine - Philadelphia in 1984. Dr. Soulen is a member of SIR.

Dr. Soulen is in network with 9 carriers, including Elevance, Excellus BlueCross BlueShield and Cigna. Medicare plans come from the most carriers, 7. Check the plan with the practice before a visit.